Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+NSCLC

被引：0
|
作者：
Lu, S. [1 ]
Fan, Y. [2 ]
Yu, Y. [3 ]
Dong, X. [4 ]
Li, J. [5 ]
Zhao, J. [6 ]
Tao, S. [7 ]
Chen, M. [7 ]
Chen, Y. [7 ]
Liu, Y. [7 ]
Xu, J. [7 ]
Hu, X. [8 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[3] Dept Med Oncol, Harbin, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[5] Sichuan Canc Hosp, Chengdu, Peoples R China
[6] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[7] Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China
[8] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
ROS1+NSCLC; Asian patients; Matching-Adjusted Indirect Comparison;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.02-12
引用
收藏
页码：S679 / S679
页数：1
相关论文
共 50 条
  • [1] Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison
    Yu, Yongfeng
    Fan, Yun
    Dong, Xiaorong
    Li, Juan
    Yu, Yan
    Zhao, Jun
    Tao, Sha
    Chen, Yujun
    Chen, Mo
    Liu, Yueming
    Xu, Jiahui
    Zhu, Qiaonan
    Hu, Xichun
    Lu, Shun
    LUNG CANCER, 2024, 198
  • [2] Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer
    Chu, Paula
    Antoniou, Miranta
    Bhutani, Mohit K.
    Aziez, Amine
    Daigl, Monica
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (12) : 861 - 876
  • [3] Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis
    Strand, Vibeke
    McInnes, Iain
    Mease, Philip
    Nash, Peter
    Thom, Howard
    Kalyvas, Chrysostomos
    Hunger, Matthias
    Gandhi, Kunal
    Pricop, Luminita
    Jugl, Steffen
    Choy, Ernest
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (07) : 497 - 510
  • [4] Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
    Armstrong, April W.
    Soliman, Ahmed M.
    Gisondi, Paolo
    Fang, Siran
    Patel, Manish
    Strober, Bruce
    DERMATOLOGY AND THERAPY, 2024, 14 (11) : 3071 - 3081
  • [5] Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
    Strand, Vibeke
    Betts, Keith A.
    Mittal, Manish
    Song, Jinlin
    Skup, Martha
    Joshi, Avani
    RHEUMATOLOGY AND THERAPY, 2017, 4 (02) : 349 - 362
  • [6] Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC
    Castro, Elena
    Wang, Di
    Walsh, Sarah
    Craigie, Samantha
    Haltner, Anja
    Nazari, Jonathan
    Niyazov, Alexander
    Samjoo, Imtiaz A.
    FUTURE ONCOLOGY, 2025, : 1075 - 1084
  • [7] Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
    Vibeke Strand
    Keith A. Betts
    Manish Mittal
    Jinlin Song
    Martha Skup
    Avani Joshi
    Rheumatology and Therapy, 2017, 4 : 349 - 362
  • [8] Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison
    Swallow, Elyse
    Song, Jinlin
    Yuan, Yong
    Kalsekar, Anupama
    Kelley, Caroline
    Peeples, Miranda
    Mu, Fan
    Ackerman, Peter
    Signorovitch, James
    CLINICAL THERAPEUTICS, 2016, 38 (02) : 404 - 412
  • [9] A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
    Edwards, Christopher J.
    Sawant, Ruta
    Garg, Vishvas
    Du, Ella X.
    Friedman, Alan
    Betts, Keith A.
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 167 - 181
  • [10] A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
    Christopher J. Edwards
    Ruta Sawant
    Vishvas Garg
    Ella X. Du
    Alan Friedman
    Keith A. Betts
    Rheumatology and Therapy, 2021, 8 : 167 - 181
12345